Browse the corpus

Esmolol, or esmolol hydrochloride, is an intravenous cardioselective β-1 adrenergic antagonist. This drug has received approval from the United States Food and Drug Administration (FDA) for short-term use in managing supraventricular tachycardia, including rapid ventricular rates in individuals with atrial fibrillation or atrial flutter, and hypertension induced by intubation. Esmolol is a valuable emergency medication for focal atrial tachycardia, particularly in individuals experiencing active bronchospasm. Furthermore, esmolol has proven to be a safe and efficient medication for controlling blood pressure during surgery due to its short half-life. The drug is also indicated in cases of sinus tachycardia, where a rapid heartbeat requires immediate intervention, especially in the case of acute coronary syndrome. Esmolol is used in various settings, including urgent care, perioperative care, and postoperative care. This drug is used off-label for managing rate and rhythm in conditions such as aortic dissection, acute coronary syndrome, non-ST elevation myocardial infarction, hypertensive emergencies, thyrotoxicosis, refractory ventricular tachycardia, ventricular fibrillation resistant to defibrillation, and for mitigating the catecholamine response during electroconvulsive therapy. This activity focuses on the indications, mechanism of action, adverse events, pharmacology, monitoring, contraindications, clinical toxicology, and relevant interactions of esmolol. This activity also highlights the crucial role of interprofessional healthcare teams involved in assessing treatment approaches and treating patients with tachycardia and related conditions where esmolol is beneficial, considering individual patient needs and potential risk factors. Objectives: Identify the appropriate indications for esmolol use, recognizing scenarios such as supraventricular tachycardia, atrial fibrillation, and hypertensive emergencies. Differentiate between the various clinical settings where esmolol is applicable, including urgent care, perioperative, and emergencies. Assess the patient's response to esmolol, monitoring vital signs, cardiac parameters, and any potential adverse events during treatment.

Identify the appropriate indications for esmolol use, recognizing scenarios such as supraventricular tachycardia, atrial fibrillation, and hypertensive emergencies. Differentiate between the various clinical settings where esmolol is applicable, including urgent care, perioperative, and emergencies. Assess the patient's response to esmolol, monitoring vital signs, cardiac parameters, and any potential adverse events during treatment. Coordinate with interprofessional healthcare teams to optimize esmolol usage within a comprehensive treatment plan, ensuring seamless integration with other therapeutic modalities and patient-centered care. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose An overdose of esmolol can result in a myriad of symptoms and effects. Cardiac signs of toxicity include but are not limited to bradycardia, AV block of any degree, complete AV dissociation, decreased contractility, cardiogenic shock, asystole, and pulseless electrical activity.[43] Neurologic signs of toxicity include but are not limited to respiratory irregularities, seizures, coma, and psychiatric symptomatology.[44] Other symptoms of toxicity may include bronchospasms, gastrointestinal mesenteric ischemia, and peripheral cyanosis. Management of Overdose Since esmolol has an ultra-short half-life, toxicity should be treated by discontinuing the infusion. Acute toxicity is often self-limited and treated supportively. Toxicity that results in bradycardia should be treated by atropine, pacing, and other anticholinergic agents. Cardiogenic shock is treated with inotropic agents such as dobutamine, dopamine, and isoproterenol. Although rare, bronchospasms are treated with a β-2 agonist, such as albuterol.[45] The Advanced Cardiac Life Support protocols should treat pulseless electrical activity and cardiac arrest. As with other β-blocker overdoses, calcium chloride is given to mitigate the effects of esmolol when metabolized. High-dose insulin euglycaemic therapy and veno-arterial extracorporeal membrane oxygenation are associated with reduced mortality.[46]

Healthcare professionals, including those in the MICU and CCU who administer esmolol, should be familiar with the adverse effects. Esmolol is an ultra-fast-acting medication that controls heart rate and pressure. Therefore, when the patient is on esmolol, it is recommended that nursing staff continuously monitor patients for blood pressure, heart rate, mean arterial pressure, and, if possible, ECG. An arterial line will provide the best continuous blood pressure monitoring method, which is beneficial when used with esmolol. The intravenous site should be checked regularly to prevent infiltration and extravasation. The pharmacist should perform medication reconciliation and inform the prescriber of any concerns. Given the pharmacodynamics of esmolol, it is advisable to use an interprofessional team approach to the drug. This interprofessional team includes clinicians, specialists, nurses, and pharmacists, all coordinating their activities and communicating openly so team members are operating from the same information and can intervene or report the need for intervention and achieve optimal patient outcomes related to esmolol therapy. According to the 2016 ESC (European Society of Cardiology), managing patients with atrial fibrillation requires coordination from an interprofessional team consisting of specialists, stroke clinicians, cardiologists, clinicians, AF surgeons, allied healthcare professionals, patients, and family members and integrated care has the potential to enhance patient outcomes.[47]